Competition For Polarity Influences Lymphocyte Differentiation And Function
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
CD46 is a protein on human cells that viruses and bacteria bind to during infection. Our laboratory has found that binding of CD46 on immune cells impairs their ability to recognize and kill target cells and may explain the immunosuppression caused by measles infection. We aim to investigate the mechanisms behind the effect of CD46 on immune cells. The outcomes of this study will define new paradigms in lymphocyte biology and determine how CD46 influences the immune response to infection.
The Role Of NKT Cell Subsets In The Regulation Of Experimental Autoimmune Encephalomyelitis
Funder
National Health and Medical Research Council
Funding Amount
$142,717.00
Summary
Multiple Sclerosis (MS) is the most common cause of paralysis in young people. EAE is an animal model of MS that recapitulates many features of the human disease. Recent data shows that EAE is mediated by IL-17 producing self-reactive T cells. NKT cells are a group of T cells, whose activation protects against EAE, in an as yet unidentified manner. These studies will provide critical information on the way in which NKT cells regulate immunity and will enhance development of therapies for MS.
Utilising Human Primary Immunodeficiencies To Study Lymphocyte Differentiation
Funder
National Health and Medical Research Council
Funding Amount
$429,346.00
Summary
Human immunodeficiencies are diseases arising from naturally occurring mutations. In this instance, the specific genes mutated in the immunodeficiencies we study have been identified. However, it is unclear how defects in these genes make an individual manifest as an immune deficient state, rendering them vulnerable to disease. By studying immune cells from these individuals we hope to uncover the normal function of these genes and subsequently provide for new therapies for these conditions.
Development Of Cancer Immunotherapy Using Gene-engineered T Cells In A Self-antigen Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$428,602.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells.